These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9814214)

  • 1. Dornase-alfa (DNase, Pulmozyme) for cystic fibrosis.
    MacConnachie AM
    Intensive Crit Care Nurs; 1998 Apr; 14(2):101-2. PubMed ID: 9814214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dornase alfa: a new option in the management of cystic fibrosis.
    Witt DM; Anderson L
    Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of recombinant human dornase alfa in CF.
    Cox C
    Paediatr Nurs; 1995 Nov; 7(9):29-31. PubMed ID: 8705343
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [2 significant stages in the management of mucoviscidosis: the French experience with dornase alfa (Pulmozyme) and the impact in international registries].
    Brémont F; Navarro J
    Arch Pediatr; 1998 Apr; 5(4):367-70. PubMed ID: 9759154
    [No Abstract]   [Full Text] [Related]  

  • 6. What is the cystic fibrosis clinician supposed to do with human recombinant dornase alfa?
    Coates AL
    J Pediatr; 2001 Dec; 139(6):768-70. PubMed ID: 11743499
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of dornase alfa in the treatment of cystic fibrosis.
    Cramer GW; Bosso JA
    Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early treatment with dornase alfa in cystic fibrosis: what are the issues?
    Bush A
    Pediatr Pulmonol; 1998 Feb; 25(2):79-82. PubMed ID: 9516089
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmozyme--Dornase alfa.
    Gutteridge C; Kuhn RJ
    Pediatr Nurs; 1994; 20(3):278-9. PubMed ID: 8008477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current therapeutic agents: dornase alfa].
    Baran D; Sternon J
    Rev Med Brux; 1997 Feb; 18(1):37-40. PubMed ID: 9132917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dornase alfa therapy in cystic fibrosis: who should get it?
    Kanga JF
    Chest; 1996 Oct; 110(4):871-2. PubMed ID: 8874235
    [No Abstract]   [Full Text] [Related]  

  • 12. Dornase alfa (Pulmozyme).
    Wagener JS; Kupfer O
    Curr Opin Pulm Med; 2012 Nov; 18(6):609-14. PubMed ID: 22990660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis--a one-year prospective study.
    Rozov T; de Oliveira VZ; Santana MA; Adde FV; Mendes RH; Paschoal IA; Caldeira Reis FJ; Higa LY; Toledo AC; Pahl M;
    Pediatr Pulmonol; 2010 Sep; 45(9):874-82. PubMed ID: 20583292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.
    Shah PL; Conway S; Scott SF; Rainisio M; Wildman M; Stableforth D; Hodson ME
    Respiration; 2001; 68(2):160-4. PubMed ID: 11287830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
    Johnson CA; Butler SM; Konstan MW; Breen TJ; Morgan WJ
    J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
    Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
    Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL; Lamb H
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dornase alpha and survival of patients with cystic fibrosis.
    McIntyre AM
    Hosp Med; 1999 Oct; 60(10):736-9. PubMed ID: 10656067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological and clinical profiles of Dornase alfa (Pulmozyme®) in the management of cystic fibrosis patients to improve pulmonary function].
    Kokubo H; Hosatani S; Ichikawa M
    Nihon Yakurigaku Zasshi; 2013 Apr; 141(4):213-9. PubMed ID: 23575427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.